Trial Profile
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS): A Randomized Phase II Study of Palbociclib With Letrozole Versus Letrozole Alone for Invasive Lobular Carcinoma and Invasive Ductal Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Letrozole; Tamoxifen
- Indications Adenocarcinoma; Breast cancer; Ductal carcinoma; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms PELOPS
- 14 Jul 2023 Results assessing the effects of ET on the tumor immune microenvironment (TME) in HR+ breast cancer published in the Cancer Research
- 21 May 2021 Planned End Date changed from 1 Nov 2020 to 1 Apr 2031.
- 21 May 2021 Planned primary completion date changed from 1 Nov 2020 to 1 Jun 2021.